Alzheimer’s study shows Sildenafil (Viagra) may reduce Alzheimers and significantly improve memory, a new study finds.
A new Cleveland Clinic-led study has identified Sildenafil (Viagra), an FDA approved therapy for erectile disfunction as a promising drug candidate to help prevent and treat Alzheimer’s disease. Study shows Sildenafil (Viagra) with a 69% Reduced Incidence of Alzheimer’s.
This is according to findings through an analysis of more than 7 million patients, researchers determined that Sildenafil is associated with a reduced incidence of Alzheimers disease. This does indicate the need for follow-up clinical trial testing of the drug’s efficacy in patients with Alzheimer’s.
Could Viagra Reduce Alzheimer’s?
During research in determining which FDA approved drugs could be an effective treatment for Alzheimer’s disease, Sildenafil (Viagra) has been shown to significantly improve cognition and memory in preclinical models. Using an existing drug therapy for new purposes offers a practical alternative the traditional drug discovery process.
The researchers utilized a large database to examine the relationship between sildenafil and Alzheimer’s disease outcomes by comparing patients that were taking sildenafil to those that were not taking sildenafil.
In the study, they used a large gene-mapping network, using genetic and other biologic data to determine which FDA-approved drugs could be most effective treatment for Alzheimer’s disease. They pinpointed drugs that target both amyloid and tau as having higher scores compared to drugs that target just one or the other. Sildenafil presented as the best candidate to be the most effective treatment for Alzheimer’s disease.
Viagra May Reduce Alzheimer’s Risk, Study Finds
The Cleveland Clinic researchers found that Sildenafil a treatment for erectile dysfunction and pulmonary hypertension is associated with a 69% reduction in developing Alzheimer’s disease. In other words, Sildenafil (Viagra)users were 69% less likely to develop Alzheimer’s disease than non-sildenafil users.
Researchers also found that Sildenafil reduced the likelihood of Alzheimer’s in patients with coronary artery disease, hypertension and type 2 diabetes.
In using an Alzheimer’s patient derived brain cell model using stem cells, findings showed Sildenafil increased brain cell growth offering insights into how Sildenafil (Viagra) may influence disease related brain changes.
Because of the researchers findings, they are planning a trial and phase ll randomized clinical trial to rest and confirm Sildenafil’s clinical benefits of Alzheimer’s patients.
For complete information on details of the study, contact the media relations team at the Cleveland Clinic.
Sildenafil for ED
ED pills like Sildenafil (Viagra) are a popular treatment option for Erectile Dysfunction (ED). Sildenafil is the generic version of Viagra, which means it contains exactly the same active ingredient (sildenafil citrate) and works in the same way. Sildenafil works by increasing blood flow to the area to help a man get and keep an erection. This drug does not protect against sexually transmitted diseases. Sildenafil belongs to a group of medicines called phosphodiesterase 5 (PDE5) inhibitors. These medicines prevent an enzyme called phosphodiesterase type-5 from working too quickly. The penis is one of the areas where this enzyme works. Read more about ED pills…
Save on many FDA-approved prescription medications with the FREE App.
DISCLAIMER: This website does not provide professional, legal, expert or medical advice. All users of this website understand and acknowledge that you are responsible for your medical care. No material on this site is intended to be a substitute for professional advice, diagnosis or treatment. All of the content, text, graphics and images are for informational purposes only. Always seek the advice of your healthcare provider. Content should be taken “as is” This website is not responsible or liable for the content provided nor does this website guarantee any product claims. Links are provided as a convenience to the visitor.